• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

Skincare Scale-Up Agreements: Who Decides When Stability Retesting Is Necessary?

You approved the lab sample, signed the scale-up agreement, and booked the first production slot for your body wash or body lotion. Then a fragrance accord gets discontinued, a botanical extract supplier changes, or…

Category: Body Care Sourcing Guides • Author: laeyo • Published: 2026-11-17 • Views: 1

You approved the lab sample, signed the scale-up agreement, and booked the first production slot for your body wash or body lotion. Then a fragrance accord gets discontinued, a botanical extract supplier changes, or your pump supplier switches resin — and someone in the email thread asks: “Do we need to re-run stability?” In most body care scale-ups, that question has no written owner. The result is either a launch that stalls for six weeks over an unclear decision, or worse, a product that ships with an unresolved shelf-life risk nobody formally accepted. This guide explains how to structure the decision inside your scale-up agreement so that “who decides” is answered before the first bulk batch, not after.

The short answer: it is a contract decision, not a lab decision

Stability retesting after a change is rarely a technical mystery. A new botanical extract, a different preservative, a reformulated fragrance, or a new bottle resin will usually change the material’s chemistry, microbial load, or interaction with the pack. The harder question is governance: who has the authority to say “retest is not required,” and who carries the consequence if that call is wrong.

In practice, three decisions have to be separated and assigned in writing:

  • Trigger. What counts as a change that enters the change-control process at all? (Supplier swap of the same INCI name is still a change.)
  • Evaluation. Once triggered, does the change require a full stability study, a targeted compatibility test, a microbial/preservative re-evaluation, or only a documented justification for no action?
  • Authority. Who signs the final decision, who may veto, and what document is filed as proof?

The commercial reality is that the manufacturer knows the process and the raw material; the brand owner owns the finished-product claim and, in most markets, the regulatory responsibility for the product’s safety and labelling. That asymmetry is why the authority to close a stability question should sit with the brand’s quality/regulatory function, informed by the manufacturer’s assessment — not delegated entirely to the filler, and not micromanaged by marketing.

Who decides what: a decision-rights table to attach to the agreement

Attach a table like the one below as an appendix to your supply or quality agreement. If it is not written down, the default is that the party with the loudest email decides — which is a poor quality system.

Decision Who decides (accountable) Who must be consulted Evidence filed
Is this change a retest trigger? Brand QA / Regulatory (product owner) Manufacturer QA, third-party lab Signed change assessment form with trigger classification
Scope of the retest Brand QA with manufacturer R&D Testing lab, packaging supplier Approved protocol listing tests, timepoints, conditions, acceptance criteria
Shelf-life claim after the change Brand owner (regulatory / Responsible Person role) Safety assessor, manufacturer Updated safety/product information file or written justification for retaining the claim
Release or hold of affected batches Manufacturer QA for release; brand for market hold — Batch record, COA, deviation and disposition report
Re-signing the Golden sample Joint: manufacturer quality + R&D, countersigned by brand — New Golden sample bound to formula version, process version and packaging version
Cost and lead-time impact Commercial owners per the agreement Project management Signed variation or purchase order referencing the change request
Escalation if no agreement within X days Named escalation contacts on both sides — Escalation log entry with dates

Informational only, not legal advice. Regulatory obligations vary by market and by who holds the Responsible Person or distributor role.

Which changes actually force a stability retest?

Body care is unforgiving here because most formats are water-based, surfactant-heavy, or packaged in pumps and tubes that interact with the formula. A useful agreement defines default classifications so the same argument is not repeated for every change order.

Change in your body care line Default status Minimum evidence before release
Botanical extract supplier change (e.g., aloe, green tea, oat in a body lotion) Retest required Stability protocol plus microbial specification review and preservative efficacy re-evaluation
Preservative system or preservative supplier change Retest + preservative challenge test Challenge test report, micro spec review, water-activity rationale
Fragrance version or fragrance house change Retest required IFRA/allergen declaration for the new version, fragrance–plastic compatibility data
Thickener or rheology modifier substitution Retest required Viscosity and pH trend at defined timepoints, sensory proxy comparison
Colorant change Retest required Color and light-exposure stability data, label claim review
Primary pack supplier, resin or decoration change (bottle, pump, cap, gasket) Compatibility test required Real-bulk compatibility report on the finished pack including decoration
Process version change (mixing speed, temperature, homogenisation time) Assess — frequently escalates to retest Process validation record, bridge data against the existing stability baseline
Manufacturing site or major equipment change Assess + bridge Method bridge report, first-batch comparison against the Golden sample
Bulk hold-time extension Retest (microbiological) Hold-time protocol, micro re-test results for the extended period
Artwork or carton copy change only No stability retest Label review sign-off and claims substantiation file

What “retest” must mean in the agreement

A clause that says “stability will be re-evaluated” is not operational. Define the deliverables. For a body wash or body lotion, a defensible re-evaluation after a material change normally covers:

  • Chemical and physical stability. Appearance, colour, odour, pH, viscosity, phase separation, and weight loss at defined timepoints, under ambient, elevated temperature, low temperature, thermal cycling, light exposure, and where relevant inverted or side-lay storage.
  • Microbiological safety. Review of the preservative system against the new raw material’s microbial load, plus a decision on whether a preservative efficacy test must be repeated. Water-based formats carry a high challenge risk and this should be treated as a launch blocker if unresolved.
  • Packaging compatibility. Testing with the real bulk in the real bottle, pump, gasket and full surface decoration — not a generic glass jar. Include leak, actuation, dip-tube fit, label adhesion and fragrance–plastic interaction checks.
  • Baseline re-establishment. A written stability baseline for the new material set: formula version, process version, initial target values, the expected drift band, and the red-flag rule (any out-of-specification result triggers investigation, not a judgement call).
  • Golden sample re-signing. The reference sample must be tied to formula, process, packaging and version. A change to any of these means the old Golden cannot simply be carried forward without a documented impact assessment.
  • Performance proxies. Where claims like “gentle cleansing” or “rich lather” cannot be re-measured every batch, agree proxies — pH, viscosity, foam, sensory panel — that are verified periodically and revalidated after any formula, process or raw material change.

Clauses to write into the scale-up agreement

  • Change notification window. The manufacturer must notify the brand in writing before implementing any raw material, supplier, process, site, or packaging change — including “same specification” substitutions. Evidence: a signed change notification form with a reference number.
  • No silent substitution. Explicit clause that INCI equivalence is not equivalence. Evidence: approved supplier and grade list attached to the specification, with a rule that deviations require written brand approval.
  • Decision turnaround. The brand commits to responding to a change assessment within a fixed number of working days; silence is not approval. Evidence: change log with timestamps and status.
  • Testing ownership and cost. State who books tests, who pays, who holds the raw data. Evidence: purchase order or cost-allocation schedule referenced in the change record.
  • Data ownership and handover. The brand receives protocols, raw data, photographs, and final reports, not only a pass/fail summary. Evidence: document register with version numbers at final handover.
  • Hold authority. The manufacturer may hold a batch, and the brand may hold a shipment, pending closure of a stability or compatibility question. Evidence: disposition record signed by QA.
  • Shelf-life re-confirmation. Any change that affects the shelf-life claim requires written re-confirmation before the affected stock is released to market. Evidence: updated claim support document.
  • Retention and ongoing monitoring. Retained finished-product samples stored under controlled conditions and reviewed at a defined timepoint plan across the shelf life. Evidence: retention register and timepoint schedule.

Realistic timeline after a change is notified

Phase Typical timing Buyer action Manufacturer action Evidence output
Notification and classification Week 0–1 Confirm trigger classification and scope Issue change request with material and process details Signed change assessment form
Impact assessment Week 1–2 Decide retest scope with QA Review specification, method bridge, Golden sample status Approved protocol and test plan
Packaging compatibility Week 2–6 Confirm pack direction and decoration Fill real bulk into real pack, run cycling and leak checks Compatibility report with photographs
Stability and micro testing Week 2–12+ Approve acceptance criteria Run timepoints, monitor trend against baseline Interim and final stability report, micro results
Label and claims review Week 3–5 Confirm no claim now exceeds the evidence Provide updated INCI, allergen and specification data Label review sign-off, updated claim support file
Pilot run Week 6–10 Approve pilot batch against Golden Produce pilot, compare against baseline Pilot batch record and comparison report
Documentation handover Before first commercial release Verify the document pack is complete Compile COA, SDS, stability, micro, compatibility, batch records Complete technical file with version control

A fastest-safe path is possible when the change is limited to decoration or artwork, or when the pack is unchanged and only a colourant shifts within an already-tested family. The standard path applies whenever the preservative system, fragrance, botanical source, or primary pack changes — compressing those is how launches get recalled rather than delayed.

Common failure modes and how to prevent them

1. The pump that worked in the lab jar

  • Symptom: Actuation becomes stiff or the pack leaks after two weeks in transit; viscosity climbs in the bottle.
  • Root cause: Compatibility tested on a generic container or on bulk that was not the final formula version.
  • Prevention: Test the real bulk in the real bottle, pump, gasket and decoration, including inverted and side-lay storage.
  • What to request from factory (evidence): A signed compatibility report listing pack components, test conditions, timepoints, leak/actuation results and photographs.

2. The missing COA or mismatched INCI

  • Symptom: Regulatory review stops because the COA, SDS and label INCI do not align with the specification on file.
  • Root cause: No document register; versions were updated separately by the lab, the filler and the brand.
  • Prevention: Make the technical file a controlled deliverable with version numbers, owned by a named person on each side.
  • What to request from factory (evidence): Current COA and SDS per raw material, the specification sheet, and the label INCI signed against the same formula version.

3. Preservative change without a challenge test

  • Symptom: A microbial excursion appears in retained samples or in market complaints; launch is blocked.
  • Root cause: The new supplier’s material was assumed equivalent because the INCI matched.
  • Prevention: Treat any preservative or botanical supplier change as a preservative-system question, not a purchasing question.
  • What to request from factory (evidence): Preservative efficacy test report on the final formula, plus a written microbial specification review.

4. Fragrance–plastic interaction

  • Symptom: Stress cracking, discolouration, or a shift in scent profile after several weeks in the pack.
  • Root cause: Fragrance version changed without re-checking the pack, or compatibility was tested with an older fragrance.
  • Prevention: Link fragrance version number to the compatibility test record; re-test when either side changes.
  • What to request from factory (evidence): Fragrance IFRA/allergen declaration matched to the tested version, and compatibility data referencing that version.

5. Bulk hold time quietly exceeded

  • Symptom: Filled units behave differently from the pilot; viscosity or odour drifts across a production run.
  • Root cause: Bulk was held beyond the validated hold time, or under different tank, mixing or temperature conditions.
  • Prevention: Define approved hold time in the protocol with tank state, mixing and temperature conditions; treat overrun as a deviation.
  • What to request from factory (evidence): Bulk hold-time validation record, plus a microbial re-test for any batch that exceeded the approved hold.

6. Golden sample carried forward after a change

  • Symptom: “Sensory drift” disputes at every batch approval; nobody can agree what the reference is.
  • Root cause: The Golden sample was not re-signed when formula, process or packaging changed.
  • Prevention: Bind the Golden sample to formula, process, packaging and version, with an impact assessment whenever a key element changes.
  • What to request from factory (evidence): Re-signed Golden sample documentation, plus limit samples for colour and appearance with defined upper and lower bounds.

Email-ready checklist for your manufacturer

Share the change notification form and reference number for this change.
Confirm whether the change is classified as a stability retest trigger.
List the raw material, supplier, grade and version affected.
State whether the INCI declaration on the label changes.
Provide the current specification sheet and COA for the new material.
Attach the SDS for the new material with the revision date.
Confirm whether the preservative system requires a new challenge test.
Provide the stability protocol with timepoints, conditions and acceptance criteria.
Confirm the storage conditions and duration for bulk hold-time validation.
Identify every pack component affected: bottle, pump, cap, gasket, decoration, label.
Attach the packaging compatibility report using real bulk in the final pack.
Provide photographs of the pack after cycling, inverted and side-lay storage.
Confirm the fragrance version number used in the compatibility test.
Provide the IFRA and allergen declaration matched to that fragrance version.
State whether any on-pack claim now exceeds the available evidence.
Provide the updated claim support file if any claim wording changes.
Confirm the Golden sample status and whether it must be re-signed.
Attach the impact assessment for the existing shelf-life claim.
Provide retained sample records under controlled storage conditions.
List the documents to be delivered at final handover, with version numbers.
Confirm the named QA contact accountable for closure on your side.
Confirm the escalation contact if the assessment is not closed on time.

FAQ

If the manufacturer says no retest is needed, can we accept that?

Only as an input, not as a conclusion. Ask for the written impact assessment showing what was evaluated — raw material chemistry, microbial load, pack interaction and the existing shelf-life claim — then have your own quality or regulatory owner sign the decision. The brand carries the market-facing consequence if a shelf-life claim fails.

Who pays for the retest?

Decide this in the agreement, not case by case. A common structure is that the party initiating the change bears the cost, with a schedule of standard test packages and prices attached to the agreement. What matters more than the split is that cost allocation never becomes the reason a test is skipped.

How long does a re-evaluation take?

Packaging compatibility is usually the shorter pole, often a few weeks. Full stability with real-time timepoints runs far longer, so most agreements allow release on interim data plus a committed continued study — with a written rule for what happens if later timepoints fail.

Is a new supplier of the same INCI name really a change?

Yes. Same INCI name does not mean same chemistry, impurity profile, microbial load or odour. Grade, processing and origin can shift viscosity, colour and preservative demand. Treat it as a change and let the assessment decide the depth of testing.

Can we launch on accelerated data only?

Accelerated and cycling data support a decision; they do not replace the ongoing monitoring of retained commercial samples under controlled conditions across the shelf life. Build the retention plan into the agreement at the same time as the retest clause.

Next step

If you are preparing a scale-up agreement, or renegotiating one after a supplier change, bring the specifics: target markets, SKU list and formats, positioning, packaging direction and your timeline target. That information turns a general enquiry into a scoped proposal with a defined change-control and stability plan attached.

Request a Quote

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).